AI-Native Scoping Reviews & Evidence Mapping

IVUS is not simply “better imaging” — this review shows where intravascular ultrasound changes real outcomes: complex coronary PCI, long lesions, diabetic ACS, femoropopliteal intervention, and iliofemoral venous disease. The full paper is worth reading because it maps when IVUS should be selectively adopted, when routine use adds little, and where AI-driven and hybrid intravascular imaging may define the next generation of endovascular precision.

This paper shows that the ischemic penumbra is not just a fading border around stroke core, but a dynamic and biologically active therapeutic target whose fate depends on collaterals, metabolism, BBB integrity, and how fast true reperfusion is achieved. The full read is worth it because it separates the real clinical signal from the hype—showing where tissue-based stroke decisions already work, where imaging and software still disagree, and which next-generation strategies may actually preserve salvageable brain.

This paper shows that Gritti-Stokes amputation may offer more than limb removal alone: in selected patients it appears to preserve a more stable, functional stump with surprisingly strong links to prosthetic fitting, mobility, and even longer-term survival. The full paper is worth reading because it clarifies where this old technique still has real modern value, which patients may benefit most, and why its outcomes may compare more favorably than many assume.

This paper shows that GLP-1 receptor agonists are no longer just metabolic drugs: across a broad evidence base, they emerge as cardioprotective therapies linked to lower MACE, stroke, mortality, and even limb events, with signals extending from atherosclerosis to heart failure and vascular biology. The full paper is worth reading because it distinguishes where the cardiovascular benefit is strongest, where arrhythmic and perioperative uncertainties remain, and why underuse in real-world practice may be limiting their true impact.

FEVAR has matured into a first-line endovascular strategy for anatomically suitable complex aortic aneurysms, delivering high technical success and low early mortality — but its real cost is lifelong surveillance and a substantial late reintervention burden. This review maps where FEVAR clearly outperforms open repair, where durability remains uncertain, and how fusion imaging, CO₂ angiography, bridging-stent choice, spinal-cord protection, and patient selection shape modern outcomes.

This paper shows that fasting diets are not just weight-loss strategies, but biologically active interventions that may improve macrovascular health through better arterial function, lower vascular inflammation, and ketone-linked protective mechanisms. It is worth reading because it also reveals the key clinical tension behind the field: vascular benefits are promising, but microvascular responses may diverge, making patient selection and endpoint interpretation crucial.

Endovascular aneurysm repair (EVAR) wins early, especially in ruptured and high-risk Abdominal aortic aneurysm — but open repair still wins durability in younger, fitter patients. This review maps where the trade-off truly lies: early survival and faster recovery versus lifelong surveillance, reintervention burden, renal decline, endoleaks, and uncertain late risks.

EVAR saves lives early, especially in ruptured abdominal aortic aneurysm, but it is not a “fit-and-forget” repair. This review maps where EVAR is strongest, where open surgery remains more durable, and why anatomy, frailty, sex-specific morphology, endoleaks, and lifelong surveillance decide the real long-term outcome.

This review shows that PAD diagnostics are shifting beyond resting ABI toward a multimodal future: post-exercise testing, advanced imaging, biomarkers, and AI repeatedly signal earlier and more precise detection, especially in patients where standard methods fail, such as those with diabetes. Read the full paper to see which emerging tools look truly promising, where the evidence is strongest, and which “innovations” still lack the validation needed for routine practice.

This review shows that AAA diagnosis is no longer just about measuring diameter: the strongest evidence now points to a multimodal pathway where ultrasound and CTA remain the clinical backbone, while CEUS, biomechanical modeling, and emerging biomarker panels begin to refine who truly carries higher rupture or surveillance risk. The full paper maps where these newer tools already add real diagnostic value, where they remain premature, and how AAA detection is shifting from simple imaging toward biologically and mechanically informed precision assessment.

Diabetic foot is not just a wound problem but a high-stakes collision of neuropathy, ischemia, infection, and delayed care, with a median major amputation rate of 10.3% across the mapped evidence. This review shows where the strongest signals truly are: why multidisciplinary care can cut major amputations by up to 80%, which risk factors matter most, and which emerging diagnostics and regenerative therapies may actually change outcomes.

This review shows where thrombolysis in DVT truly helps and where it does not: the clearest signal is in selected iliofemoral disease, where modern catheter-based clot removal may improve patency and reduce post-thrombotic syndrome, but only at the cost of real bleeding risk. Read the full paper to see which techniques look most promising, which patients benefit most, and where the evidence still breaks down.